Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Therapeutics says live and archived webcasts of management’s investor fireside chat are available in the Investors section of its website.
Rhea-AI Summary
Rapport Therapeutics (RAPP) will participate in two upcoming investor events in September 2026. Management will host a fireside chat at the Cantor Global Healthcare Conference in New York City on September 9, 2026, from 1:35–2:05 pm ET, and at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit (virtual) on September 23, 2026, from 1:30–1:55 pm ET. Live and archived webcasts will be available in the Investors section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – RAPP
In the Sep 2 session, RAPP gained 0.27%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events:
Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 2026, at 1:35-2:05 pm ET.
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit (virtual) – fireside chat on Wednesday, September 23, 2026, at 1:30-1:55 pm ET.
Interested parties may access the live and archived webcasts of these fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.
Investor Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
investors@rapportrx.com
